These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32690107)

  • 1. Are supplemental appraisal/reimbursement processes needed for rare disease treatments? An international comparison of country approaches.
    Nicod E; Whittal A; Drummond M; Facey K
    Orphanet J Rare Dis; 2020 Jul; 15(1):189. PubMed ID: 32690107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining the impact of different country processes for appraising rare disease treatments: a case study analysis.
    Whittal A; Nicod E; Drummond M; Facey K
    Int J Technol Assess Health Care; 2021 May; 37(1):e65. PubMed ID: 34044899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products.
    Lee D; McCarthy G; Saeed O; Allen R; Malottki K; Chandler F
    Pharmacoecon Open; 2023 Mar; 7(2):175-187. PubMed ID: 36315388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?
    Menon D; Stafinski T; Dunn A; Short H
    Patient; 2015 Feb; 8(1):29-39. PubMed ID: 25516506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries.
    Blonda A; Denier Y; Huys I; Kawalec P; Simoens S
    Front Pharmacol; 2022; 13():902150. PubMed ID: 35928274
    [No Abstract]   [Full Text] [Related]  

  • 7. How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework.
    Johannesen KM; Claxton K; Sculpher MJ; Wailoo AJ
    Health Econ; 2018 Feb; 27(2):e41-e54. PubMed ID: 28833844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A National Approach to Reimbursement Decision-Making on Drugs for Rare Diseases in Canada? Insights from Across the Ponds.
    Short H; Stafinski T; Menon D
    Healthc Policy; 2015 May; 10(4):24-46. PubMed ID: 26142357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Front Public Health; 2016; 4():214. PubMed ID: 27747207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 11. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
    Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
    Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating public preferences into national reimbursement decisions: a descriptive comparison of approaches in Belgium and New Zealand.
    Leopold C; Lu CY; Wagner AK
    BMC Health Serv Res; 2020 Apr; 20(1):351. PubMed ID: 32334579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
    Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
    Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using automated text classification to explore uncertainty in NICE appraisals for drugs for rare diseases.
    Wiedmann L; Blumenau J; Carroll O; Cairns J
    Int J Technol Assess Health Care; 2024 Jan; 40(1):e5. PubMed ID: 38178720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consideration of quality of life in the health technology assessments of rare disease treatments.
    Nicod E; Meregaglia M; Whittal A; Upadhyaya S; Facey K; Drummond M
    Eur J Health Econ; 2022 Jun; 23(4):645-669. PubMed ID: 34714428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.